Your session is about to expire
← Back to Search
Cancer Vaccine
Cohort 1: 1 x 10^8 INKmune for Cancer (CaRe Trial)
Phase 1 & 2
Recruiting
Research Sponsored by Inmune Bio, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
viii. Bilirubin < 1.5x ULN (< 3x ULN in Gilbert's Syndrome). ix. Creatinine clearance/estimated GFR ≥ 50 mL/min (MDRD or Cockcroft-Gault). x. Resting room air PaO2 saturation of >95% as measured by pulse oximetry.
A diagnosis of progressive metastatic castrate resistant prostate cancer (mCRPC), as defined by Prostate Cancer Clinical Trials Working Group 3 (PCWG3), following androgen deprivation therapy (ADT) and at least one androgen receptor signaling inhibitor, but not more than 3 therapies in addition to ADT. Progressive disease at the time of study entry as indicated by at least one of the following: i. At least two rising PSA values at a minimum of a one-week interval. If PSA is the only measure of progression, then the minimum PSA value at the start of treatment must be ≥ 1 ng/mL. ii. Radiographic progression per RECIST1.1 for soft tissue (at least 1 measurable lesion per RECIST 1.1), and/or iii. Progression of bone metastases.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2-3 years
Awards & highlights
CaRe Trial Summary
This trial is testing a treatment called INKmune in men with advanced prostate cancer. INKmune is given to patients through a vein in three separate doses, with at least one week in
Who is the study for?
Men over 18 with advanced prostate cancer that's resistant to hormone therapy and has progressed after treatment. They must have a PSA level >1.0 ng/ml, be in good physical condition (ECOG 0-1), and agree to use effective contraception during the study and for three months after.Check my eligibility
What is being tested?
The trial is testing INKmune, given intravenously in three doses at least one week apart. It's an open-label phase I/IIa study which means everyone gets the drug, and it includes dose escalation to find the right amount followed by expansion to see how well it works.See study design
What are the potential side effects?
Specific side effects of INKmune are not listed here, but common ones for similar immune therapies may include flu-like symptoms, fatigue, fever, chills, weakness, nausea or vomiting.
CaRe Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
Your bilirubin level is below 1.5x the upper limit of normal (< 3x ULN in Gilbert's Syndrome), your creatinine clearance/estimated GFR must be at least 50 mL/min (MDRD or Cockcroft-Gault) and your resting room air PaO2 saturation needs to measure above 95% as measured by pulse oximetry.
Select...
I have advanced prostate cancer that has worsened despite hormone therapy and up to three other treatments.
Select...
I am fully active or can carry out light work.
Select...
My prostate cancer is confirmed to be adenocarcinoma.
Select...
I am a man over 18 years old.
Select...
My testosterone levels are below 50 ng/dL.
CaRe Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2-3 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2-3 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Determine the optimal concentration of INKmune therapy to be used in patients with mCRPC.
Evaluate the safety and tolerability of INKmune therapy in patients with mCRPC.
Secondary outcome measures
Evaluate the overall clinical efficacy of INKmune treatment in patients utilizing PSA.
Evaluate the overall clinical efficacy of INKmune treatment in patients utilizing RECIST.
Evaluate the overall clinical efficacy of INKmune treatment in patients utilizing disease response.
+1 moreOther outcome measures
Assess persistence of memory like Natural Killer (NK) cell number.
Assess the experience of clinical trial participation by patients through a comprehensive patient survey provided post visit at 3 timepoints during the trial.
Complete transcriptomic analyses from optional biopsy tissue and previously resected tissue (if available).
+6 moreCaRe Trial Design
3Treatment groups
Experimental Treatment
Group I: Cohort 3: 5 x 10^8 INKmuneExperimental Treatment1 Intervention
In Dose Escalation: INKmune therapy will be administered by a slow intravenous injection via conventional blood giving set. Approximately 18 patients will receive 3 weekly IV doses of INKmune on Day 1, 8, and 15 as per the below:
In Cohort 1, the initial planned dose is 1 x 10^8 INKmune;
In Cohort 2, the weekly dose will increase to 3 x 10^8 INKmune;
In Cohort 3, the weekly dose will increase to 5 x 10^8 INKmune.
In Dose Expansion: INKmune therapy will be administered by a slow intravenous injection via conventional blood giving set. Approximately 12 patients will receive 3 weekly IV doses of INKmune on Day 1, 8, and 15 as per the below:
Following mBOIN termination and MTD identification, patients will be enrolled in up to two candidate optimal dose levels (no higher than the MTD) for final optimal dose determination.
Group II: Cohort 2: 3 x 10^8 INKmuneExperimental Treatment1 Intervention
In Dose Escalation: INKmune therapy will be administered by a slow intravenous injection via conventional blood giving set. Approximately 18 patients will receive 3 weekly IV doses of INKmune on Day 1, 8, and 15 as per the below:
In Cohort 1, the initial planned dose is 1 x 10^8 INKmune;
In Cohort 2, the weekly dose will increase to 3 x 10^8 INKmune;
In Cohort 3, the weekly dose will increase to 5 x 10^8 INKmune.
In Dose Expansion: INKmune therapy will be administered by a slow intravenous injection via conventional blood giving set. Approximately 12 patients will receive 3 weekly IV doses of INKmune on Day 1, 8, and 15 as per the below:
Following mBOIN termination and MTD identification, patients will be enrolled in up to two candidate optimal dose levels (no higher than the MTD) for final optimal dose determination.
Group III: Cohort 1: 1 x 10^8 INKmuneExperimental Treatment1 Intervention
In Dose Escalation: INKmune therapy will be administered by a slow intravenous injection via conventional blood giving set. Approximately 18 patients will receive 3 weekly IV doses of INKmune on Day 1, 8, and 15 as per the below:
In Cohort 1, the initial planned dose is 1 x 10^8 INKmune;
In Cohort 2, the weekly dose will increase to 3 x 10^8 INKmune;
In Cohort 3, the weekly dose will increase to 5 x 10^8 INKmune.
In Dose Expansion: INKmune therapy will be administered by a slow intravenous injection via conventional blood giving set. Approximately 12 patients will receive 3 weekly IV doses of INKmune on Day 1, 8, and 15 as per the below:
Following mBOIN termination and MTD identification, patients will be enrolled in up to two candidate optimal dose levels (no higher than the MTD) for final optimal dose determination.
Find a Location
Who is running the clinical trial?
Inmune Bio, Inc.Lead Sponsor
6 Previous Clinical Trials
570 Total Patients Enrolled
Tara LehnerStudy DirectorINmune Bio
2 Previous Clinical Trials
261 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are individuals currently eligible to apply for participation in this ongoing medical study?
"Indeed, the information available on clinicaltrials.gov confirms that this particular trial is presently seeking participants. The initial posting of the clinical trial occurred on November 30th, 2023 and it was most recently updated on January 8th, 2024. The study aims to enroll a total of 30 individuals distributed across eight distinct locations."
Answered by AI
At present, how many locations are hosting this particular clinical trial?
"Among the several other recruiting locations, some notable ones include University of California, Los Angeles in Las Vegas, Comprehensive Cancer Centers of Nevada in Cincinnati, and Carl & Edyth Lindner Center for Research and Education at The Christ Hospital and The Christ Hospital Cancer Center in El Paso."
Answered by AI
What is the primary aim of conducting this clinical investigation?
"The study sponsor, Inmune Bio, Inc., aims to assess the safety and tolerability of INKmune therapy over a period of 2-3 years in patients with mCRPC. Additionally, secondary outcomes will be evaluated including overall clinical efficacy measured by survival data (overall survival or OS), disease response (disease control rate), and prostate-specific antigen (PSA) levels below baseline."
Answered by AI
What is the current number of patients undergoing treatment in this medical study?
"The successful execution of this study necessitates the enrollment of 30 eligible participants. Inmune Bio, Inc., as the sponsor, will oversee the trial's implementation across various locations, including the University of California in Los Angeles (located in Las Vegas, Nevada) and Comprehensive Cancer Centers of Nevada (based in Cincinnati, Ohio)."
Answered by AI
Recent research and studies
New England Journal of MedicineJournal
Enzalutamide in Metastatic Prostate Cancer Before ChemotherapyOther Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger